ANRis Pharmaceuticals Inc.
ANRis Pharmaceuticals has developed a non-liposomal nanoparticle delivery technology that can be tailored to deliver its RNA payload to a variety of tissues and organs beyond the liver. The ability to target other tissues and organs (e.g., kidney, lung, brain) is extremely limited and currently not possible with liposomes. ANRis’ Polymeric Nanoparticles (PNs) target the kidney with precision and are being modified to target other tissues and organs.
Three targeting programs:
1. Naked Polymeric Nanoparticle (NPN): IV administration targets proximal kidney
2. Coated Polymeric Nanoparticle (CPN): hemocompatible to deliver 8mg/kg RNA
3. PEGylated Polymeric Nanoparticle (PPN): attachment of targeting ligands
ANRis’ NPN and CPN target the kidney with great precision. Delivering siRNAs and mRNAs that target the proximal nephron, which is the primary site of kidney damage in diabetes.
Diabetic nephropathy (DN) is the major cause of chronic kidney disease (CKD) which is a US $11 billion market. ANRis is undertaking in vivo proof-of-concept (PoC) in models of late-stage DN. Late stage DN is a clinical target which will produce a quick readout to demonstrate efficacy of delivering disease modifying RNA drugs to the diabetic kidney. Major pharma players in the CKD have expressed interest in ANRis’ kidney program and are awaiting results of the PoC studies.